Statistical primer on biosimilar clinical development

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1903-e1910

  Isakov, Leah ^a   Jin, Bo ^a   Jacobs, Ira Allen ^a  

^a PFIZER INC   (United States)

Author keywords

Biosimilar; Equivalence; Statistical analyses

Indexed keywords

BIOSIMILAR AGENT;

CANCER THERAPY; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STUDY DESIGN; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; NOMENCLATURE; STATISTICS;

BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; STATISTICS AS TOPIC; TERMINOLOGY AS TOPIC;

EID: 84954338760     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000391     Document Type: Review

References (33)

1. European Medicines Agency. Guideline on Similar Biological Medicinal Products. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific- guideline/2014/10/WC500176768.pdf. Accessed June 5, 2015.
2. U.S. Food and Drug Administration. Guidance for Industry: Scientific Considerations inDemonstrating Biosimilarity to a Reference Product. Draft Guidelines. U.S. Department of Health and Human Services Food and Drug Administration; 2015. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf. Accessed April 7, 2015.
3. World Health Organization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at: http:// www.who.int/biologicals/areas/biological-therapeutics/ BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed April 7, 2015.
4. Tsong Y, Dong X, Shen M. Development of statistical methods for analytical similarity assessment. J Biopharm Stat. 2015 Sep 15. [Epub ahead of print].
5. U.S. Food and Drug Administration. Guidance for Industry E9 Statistical Principles for Clinical Trials. U.S. Department of Health and Human Services Food and Drug Administration; 1998. Available at: http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/ guidances/ucm073137.pdf. Accessed July 1, 2015.
6. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26:192-196.
7. Dasgupta A, Lawson KA, Wilson JP. Evaluating equivalence and noninferiority trials. Am J Health Syst Pharm. 2010;67:1337-1343.
8. Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals. 2011;39:266-269.
9. SAS Institute Inc. SAS/STAT 9.2 User's Guide. TOST Equivalence Test. 2nd ed. Available at: http://support. sas.com/documentation/cdl/en/statug/63033/HTML/ default/viewer.htm#statug-ttest-a0000000128.htm. Accessed July 2, 2015.
10. United States Food and Drug Administration. Guidance for Industry Non-Inferiority Clinical Trials. Draft Guidance. Available at: http://www.fda.gov/downloads/ Drugs/./Guidances/UCM202140.pdf. Accessed September 24, 2015.
11. SAS Institute Inc. SAS/STAT 9.2 User's Guide [computer Program]. Version 2. SAS Institute Inc., Cary, NC; 2010.
12. Chow SC, Liu JP. Statistical assessment of biosimilar products. J Biopharm Stat. 2010;20:10-30.
13. U.S. Food and Drug Administration. Guidance for Industry Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration; 2014. Available at: http://www. fda.gov/downloads/drugs/guidancecomplianceregula toryinformation/guidances/ucm397017.pdf. Accessed July 1, 2015.
14. Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and number needed to treat. Kidney Int. 2007;72:789-791.
15. U.S. Food and Drug Administration. Guidance for Industry Statistical Approaches to Establishing Bioequivalence. U. S. Department of Health and Human Services Food and Drug Administration; 2001. Available at: http://www. fda.gov/downloads/drugs/guidancecomplianceregula toryinformation/guidances/ucm070244.pdf. Accessed July 1, 2015.
16. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109-112.
17. Botrel TE, Clark O, Clark L, et al. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer. 2011;74:89-97.
18. Genentech Inc. Avastin (Bevacizumab) Prescribing Information. South San Francisco, CA. Available at: http:// www.gene.com/download/pdf/avastin-prescribing. pdf. Accessed September 4, 2015.
19. Roche. Summary of Product Characteristics. Avastin (Bevacizumab). Available at: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/ human/000582/WC500029271.pdf. Accessed September 4, 2015.
20. Socinski MA, Curigliano G, Jacobs I, et al. Clinical considerations for the development of biosimilars in oncology. MAbs. 2015;7:286-293.
21. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2009/ 09/WC500003946.pdf. Accessed July 15, 2015.
22. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
23. Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76:362-367.
24. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804-1809.
25. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
26. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.
27. Dougados M, Schmidely N, Le Bars M, et al. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis. 2009;68:484-489.
28. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
29. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69: 1629-1635.
30. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-1400.
31. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23: S93-S99.
32. Volkmann E, Agrawal H, Maranian P, et al. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med Insights. 2010;2:749-760.
33. Gaujoux-Viala C, Mouterde G, Baillet A, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine. 2012; 79:149-155.